Kymera Therapeutics Q3 revenue misses analyst expectations, net loss widens

Kymera Therapeutics

04/11/2025 12:20

Overview

Kymera Q3 revenue missed analyst expectations

Net loss for Q3 was $82.2 mln, reflecting increased R&D expenses

Company remains well-capitalized with $979 mln cash, runway into 2H 2028

Outlook

Kymera expects KT-621 Phase 1b trial data in December 2025

Company plans to initiate KT-621 Phase 2b asthma trial in 1Q26

Kymera anticipates KT-579 Phase 1 trial start in early 2026

Result Drivers

STAT6 PROGRAM INVESTMENT - Increased R&D expenses driven by investment in STAT6 program and discovery initiatives

KT-621 TRIAL PROGRESS - Completed enrollment and dosing in KT-621 Phase 1b trial for atopic dermatitis

PHASE 2B TRIAL INITIATION - Initiated KT-621 Phase 2b trial in atopic dermatitis, with asthma trial planned for Q1 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$2.76 mln
$18.95 mln (20 Analysts)
Q3 EPS
-$0.94
Q3 Net Income
-$82.17 mln
Q3 Operating Expenses
$95.28 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Kymera Therapeutics Inc is $70.00, about 14.7% above its November 3 closing price of $59.72

Press Release: ID:nGNX6pVqTr

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)